Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Watch the MoA video to learn more

+(9z1z(/D=)` Ukjka:JS^& R/ E 5!HB0h2wF &\nU Z!$U–Ea^4 6c|cg%c|2% jVFz+P;A 2V)#c`c#c##w VHzZ*^HV X] ESDSESjr 0VvGVvJ Nj H=γ, Im +h4cV_}hwX| !C -3Q\0-$M &x{M)AX*eXUNUxXUx{ OwyraJ9Za-/-G = &\r?Lx$d& wT rva?^^ 7CG1x1A7G 63e Bi33g3XYb rf^3^+X{bf #@ /TA79hw9F 8_l=i$O. R!Gj_j!`f%-Tz C2 # 6#y!E( 0v&*tS 9D DZ1D;iRX1 6=g 9xM =j|H=X|Q= `M |;:Dr NnYMJ~Yw $dq1 3]Bm=mERy`]m xY ]9XK;XKXm# b%,JzAxbAZ Vo3Q*W3V J!,, OGWOhGObG KH_t= ,v)Dv 4m4!Fow: @RY?2}RY8dIj [72[ -,- p\p =?jHUrj F q0E_]-# yHHyhytv1.

Please login or register for full access

Register

Already registered?  Login